Amit J Sabnis (A J Sabnis)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Childhood Cancer

Top Venues

JCO precision oncology

Science (New York, N.Y.)

This page only lists publications with an associated author ORCID identifier.

Publications

Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Alok I Jaju, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, Donald Williams Parsons
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO precision oncology 8 (2024)
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Alok I Jaju, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, Donald Williams Parsons
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO precision oncology 8 (2024)
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Alok I Jaju, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, Donald Williams Parsons
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO precision oncology 8 (2024)
Amanda E Marinoff, Liam F Spurr, Christina Fong, Yvonne Y Li, Suzanne J Forrest, Abigail Ward, Duong Doan, Laura B Corson, Audrey Mauguen, Navin R Pinto, Luke D Maese, Susan I Colace, Margaret E Macy, AeRang Kim, Amit J Sabnis, Mark A Applebaum, Theodore W Laetsch, Julia L Glade Bender, Daniel A Weiser, Megan Anderson, Brian D Crompton, Paul A Meyers, Ahmet Zehir, Laura Macconaill, Neal Lindeman, Jonathan Andrew Nowak, Marc Ladanyi, Alanna J Church, Andrew D Cherniak, Neerav N Shukla, Katherine A Janeway
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO precision oncology 7 (2023)
Lorena Lazo De La Vega, Hannah Comeau, Sarah Sallan, Alyaa Al-Ibraheemi, Hersh V Gupta, Yvonne Y Li, Harrison K Tsai, Wenjun Kang, Abigail Ward, Alanna J Church, AeRang Kim, Navin R Pinto, Margaret E Macy, Luke D Maese, Amit J Sabnis, Andrew D Cherniack, Neal I Lindeman, Megan E Anderson, Tabitha M Cooney, Kee Kiat Yeo, Gregory H Reaman, Steven G DuBois, Natalie B Collins, Bruce E Johnson, Katherine A Janeway, Suzanne J Forrest
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO precision oncology 6 (2022)
Lukasz J Bugaj, Amit J Sabnis, Amir Mitchell, J E Garbarino, Jared E Toettcher, T G Bivona, Wendell A Lim
Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science (New York, N.Y.) 361 (6405) (2018)